Dr. Larry Kaiser
Dr. Larry Kaiser is a specialist in lung cancers and mesothelioma cases. He graduated with his Medical Degree from Tulane University and continued his education with an internship and residency in surgery at the University of California at Los Angeles. Upon completion of his residency at UCLA he finished his education in Cardiovascular and Thoracic Surgery at the University of Toronto. While at the University of Toronto he served as senior resident in Thoracic Surgery. He then joined the Memorial Sloan-Kettering Cancer Center in the department of Thoracic Services. In 1988 he became an Associate Professor at the Washington University School of Medicine, earning tenure in 1990.
Dr. Kaiser then took the positions of Associate Professor of Surgery, Chief of General Thoracic Surgery, Founder and Director of the Lung Transplantation Program, and Director of the Center of Lung Cancer and Related Disorders at the University of Pennsylvania Health System. He currently works at the University of Texas Health Science Center at Houston.
Dr. Kaiser is affiliated with many professional surgical societies, has written over 250 original papers and is the author or co-author of thirteen books. He also served or serves on the editorial boards of many surgical journals such as the Annals of Surgery. He was elected to the Institute of Medicine of the National Academy of Sciences in 2005. His clinical expertise involves lung cancer, malignant mesothelioma and mediastinal tumors. He is a proponent of gene therapies and the molecular biology of lung cancer and mesothelioma. In one gene therapy study he, along with other doctors, studied the affect of the adenoviral gene transfer, which sought to discover how the somatic gene transfer affected pleural based mesothelioma.
Other research of Dr. Kaiser has concluded that the malignant mesothelioma could be a candidate for somatic gene therapy with replication-deficient recombinant adenovirus transfer of a toxic, or drug sensitization gene. This drug sensitization gene is the herpes simplex thymidine kinase type one gene, which when followed by exposure to the acyclic nucleoside drug, gancicolovir, creates a tumor cell killing system.
- University of Texas M.D. Anderson Cancer Center. Physician Profile.
Last modified: December 24, 2010.